Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company Information
- CEO
- Pascal Claude Roland Soriot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 94300
Contact Information
- Website
- https://www.astrazeneca.com
- Address
- 1 Francis Crick Avenue
- Country
- GB
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 245.26B market capitalization
- Trading Volume: 2.85M shares traded today
- Price Range: 52-week range of $61.24 - $87.68
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for AstraZeneca PLC
AstraZeneca PLC (AZN) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 245.26B, the company represents a significant player in its market. The stock is currently trading at $79.12 with a negativedaily change of 0.06%.
The company's 94300 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 29.86, beta of 0.15, and 52-week price range from $61.24 to $87.68when evaluating investment opportunities.
Why Invest in AstraZeneca PLC?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Pascal Claude Roland Soriot
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.